Company Overview of Agency for Science, Technology and Research
Agency for Science, Technology and Research operates as an agency for fostering scientific research and talent in Singapore. It nurtures public sector research and development in biomedical sciences, physical sciences, and engineering; and supports economic clusters by providing intellectual, human, and industrial capital to its partners in industry and healthcare sectors. The company supports, oversees, and coordinates public sector biomedical research and development activities; supports the development and growth of research scientists and engineers through secondment and attachment programs; manages the intellectual property created by research institutes and facilitates the transfer of ...
1 Fusionopolis Way
#20-10 Connexis North Tower
Founded in 2002
Key Executives for Agency for Science, Technology and Research
Managing Director and Executive Director
Chief Executive Officer of IE Singapore
Deputy Managing Director of Corporate & Legal and General Counsel
Chairman of Biomedical Research Council and Director
Executive Chairman of Exploit Technologies Pte Ltd
Compensation as of Fiscal Year 2012.
Agency for Science, Technology and Research Key Developments
Agency for Science, Technology and Research and Cytos Biotechnology AG Bring First Influenza Vaccine to Clinical Testing
May 17 13
Agency for Science, Technology and Research and Cytos Biotechnology AG announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their H1N1 influenza vaccine candidate based on Cytos' proprietary bacteriophage Qbeta virus-like particle technology. In this first Phase 1 clinical trial, the safety and immunogenicity of this novel vaccine candidate and its potential to protect against H1N1 influenza infection will be evaluated.
GlaxoSmithkline Bangladesh Ltd. and Agency for Science, Technology and Research Sign a Five-Year Strategic Agreement to Develop New Evidence Based Formulations
Apr 9 13
GlaxoSmithKline Bangladesh Ltd. and Agency for Science, Technology and Research have signed a five-year strategic agreement to develop new evidence based formulations (EBFs) specifically for emerging markets. EBFs are medicines which are reformulated to provide additional patient benefit. The collaboration will enhance ICES' technical expertise and know-how in drug product formulation, analytical techniques, development and scale up. It will develop a pool of local expertise in specialised formulation for pharmaceutical development in Singapore. The establishment of a joint partnership between ICES and GSK will position Singapore as a regional centre for drug development for the emerging markets. This agreement with ICES is perfectly aligned with GSK's strategic priority of growing a diversified global business, whilst bringing affordable, quality GSK medicines of value to more people who need them.
Agency for Science, Technology and Research Announces Board Appointments
Feb 1 13
Agency for Science, Technology and Research announced three new members to board. Isaac Ben-Israel, chairman of Israel Space Agency; Jonathan Knowles, distinguished professor at the Institute for Molecular Medicine Finland (FIMM); and Keith O'Nions, president and rector, Imperial College.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|